Table 3

Biomarkers for which differences between persons from the KORA F4 study with normal glucose tolerance (NGT, n=354) and either patients without diabetic sensorimotor polyneuropathy (DSPN−, n=158) or those with DSPN (DSPN+, n=304; PROPANE study) or both were noted

BiomarkersNGTDSPN−DSPN+P value*
 IL62.22±0.812.58±0.73†‡§2.57±0.83 †‡1.4×10−13
 CCL19 (MIP-3β)9.80±0.9210.06±0.87†10.28±0.95†‡§9.7×10−13
 CCL23 (MIP-3)9.98±0.4710.02±0.4910.15±0.77†‡§1.9×10−4
 CCL25 (TECK)6.63±0.586.71±0.546.89±0.60†‡§2.1×10−7
Growth factors
 MMP10 (SL-2)6.41±0.586.51±0.666.61±0.62†‡6.9×10−6
 SLAMF1 (CD150)2.41±0.502.73±0.60†‡2.74±0.58†‡1.2×10−17
  • Data are expressed as mean±SD (the unit is normalized protein expression (NPX) which is comparable in its distribution to log2-transformed protein concentration).

  • *Kruskal-Wallis test with Bonferroni correction (p<2.35×10−4).

  • †P<0.05 versus NGT group after adjustment for model 1: sex, age, and smoking.

  • ‡P<0.05 versus NGT group after adjustment for model 2: model 1+BMI.

  • §P<0.05 versus NGT group after adjustment for model 3: model 2+HbA1c.

  • BMI, body mass index; CCL, chemokine (C-C motif) ligand; CD, cluster of differentiation; FGF, fibroblast growth factor; IL6, interleukin 6; KORA, Cooperative Health Research in the Region of Augsburg; MIP, macrophage inflammatory protein; PROPANE, Probing the Role of Sodium Channels in Painful Neuropathy Study; SIRT2, SIR2-like protein; SL-2, stromelysin-2; ST1A1, sulfotransferase 1A1; TECK, thymus-expressed chemokine; uPA, urokinase-type plasminogen activator.